Keywordsnucleocapsid protein; influenza virus A virus; amino acid substitution; mass spectrometry; mass spectrometry; HIP-55; phosphorylation; benzene; endogenous metabolites; bone marrow; plasma; HPLC-TOF-MS; IL-6R; polymorphisms; left main artery; coronary artery disease; mass spectrometry; human milk oligosaccharides; MALDI Q-TOF (matrix-assisted laser desorption/ionization quadrupole-time-of-flight) MS (mass spectrometry); CID (collision-induced dissociation); diagnostic ion MS; de novo sequencing; dose-volume effect; intensity-modulated radiation therapy; mass spectrometry; radiation toxicity; serum lipidome; affinity probes; bacteria; matrix-assisted laser desorption/ionization mass spectrometry; nanomaterials; LC/ESI-MS; MALDI-TOF; Legionella dumoffii; phosphatidylcholine; TNF-α; proteins; hydrogen-radical; flexibility; MALDI MS (matrix-assisted laser desorption/ionization mass spectrometry); in-source decay; histone H2A; proteolysis; histone clipping; chronic lymphocytic leukemia; THP-1 cells; quantitative proteomics; hCG; hCGβcf; MALDI TOF MS; pregnancy; hydatidiform mole; hyperemesis gravidarum; glycosylation; mass spectrometry; atmospheric pressure laser ionization; mid-infrared tunable laser; peptides; imaging mass spectrometry; laser ionization; anticancer drug; drug resistance; zeolite matrix; mass spectrometry; eukaryotic initiation factor; translation; phosphorylation quantification; small-molecule kinase inhibitors; VE-821; ATR kinase; DNA damage response; radio-sensitization; quantitative phosphoproteomics; titanium dioxide chromatography; SILAC; leukemia; HL-60 cells
